Company intelligence / Profile preview

Taiwan Medtech Fund

Taiwan

Ownership: Private
Development stage: Other

Overview

Taiwania Capital is a prominent Taiwan-based venture capital firm with a focus on healthcare, managing dedicated funds like Fund III (Medtech) and Fund II (Biotech). They invest in portfolio companies such as AmMAX (anti-cancer therapeutics), AnHorn Medicines (innate mechanism drugs), and Bigfoot Biomedical (diabetes devices), aiming to bridge Taiwanese innovations to global markets.

Industry: Investors

Partnerships

Axil Capital Group

Beyond the preview

Go deeper on Taiwan Medtech Fund.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Taiwan Medtech Fund.

Explore the full profile